Cancers, Vol. 15, Pages 5787: Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy

Cancers, Vol. 15, Pages 5787: Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy Cancers doi: 10.3390/cancers15245787 Authors: Susana Cedres Augusto Valdivia Patricia Iranzo Ana Callejo Nuria Pardo Alejandro Navarro Alex Martinez-Marti Juan David Assaf-Pastrana Enriqueta Felip Pilar Garrido Malignant pleural mesothelioma (MPM) is a locally aggressive disease related to asbestos exposure with a median survival for untreated patients of 4–8 months. The combination of chemotherapy based on platinum and antifolate is the standard treatment, and the addition of bevacizumab adds two months to median survival. Recently, in first-line treatment, immunotherapy combining nivolumab with ipilimumab has been shown to be superior to chemotherapy in the CheckMate-743 study in terms of overall survival (18.1 months), leading to its approval by the FDA and EMA. The positive results of this study represent a new standard of treatment for patients with MPM; however, not all patients will benefit from immunotherapy treatment. In an effort to improve the selection of patient candidates for immunotherapy for different tumors, biomarkers that have been associated with a greater possibility of response to treatment have been described. MPM is a type of tumor with low mutational load and neo-antigens, making it a relatively non-immunogenic tumor for T cells and possibly less susceptible to responding...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research